Pediatric Phase 2/3 Trial to Test Anti-myostatin Antibody with Evrysdi

Pediatric Phase 2/3 Trial to Test Anti-myostatin Antibody with Evrysdi

310156

Pediatric Phase 2/3 Trial to Test Anti-myostatin Antibody with Evrysdi

Roche and its subsidiary Genentech are launching a Phase 2/3 clinical trial to evaluate the safety and efficacy of GYM329 (RO7204239), an investigational anti-myostatin antibody, in combination with Evrysdi (risdiplam) in children with spinal muscular atrophy (SMA). The MANATEE trial has two parts. In part one, 36 patients, age 2 to 10, will be tested to determine the best dose of GYM329 for further testing. This part of the trial will take place at approximately 15…

You must be logged in to read/download the full post.